Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655883 · ClinicalTrials.gov registry record · Phase 3
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
A Phase 3 study of Insomnia, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 10
- Study locations
NCT06655883 is a Phase 3 study of Insomnia that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 300 participants, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (79% higher). The trial reports 10 study locations across 9 states.
The verdict
NCT06655883, a Phase 3 study of Insomnia, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 10
- Study locations
Study Summary
People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Suvorexant
Study Locations (10)
Texas
- Adams Clinical Dallas ( Site 2007) - DeSoto
- Memorial Hermann Village ( Site 2001) - Houston
Connecticut
- Yale University School of Medicine ( Site 1003) - New Haven
Georgia
- CenExel iResearch, LLC ( Site 2010) - Savannah
Maryland
- Johns Hopkins University ( Site 1001) - Baltimore
New Jersey
- Hassman Research Institute Marlton Site ( Site 2005) - Marlton
Oklahoma
- The Rivus Wellness & Research Institute ( Site 2014) - Oklahoma City
Pennsylvania
- Penn Medicine University of Pennsylvania Health System- Center for Studies of Addiction ( Site 1006) - Philadelphia
Rhode Island
- Butler Hospital ( Site 1002) - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2027-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06655883
The ClinicalTrials.gov registry entry for NCT06655883 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 151 other Insomnia trials with a reported enrollment target (79% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06655883 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT06655883 about?
NCT06655883 is a clinical study titled "A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)". People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to ...
What is the current status of trial NCT06655883?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-10-09. Estimated completion is 2027-06-24.
What conditions does trial NCT06655883 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT06655883?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT06655883?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06655883 being conducted?
This trial has 10 study locations across Connecticut, Georgia, Maryland, New Jersey, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
National Adaptive Trial for PTSD Related Insomnia
ACTIVE NOT RECRUITING · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
COMPLETED · Phase 3
-
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
RECRUITING
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.